# Nanobiotix S.A. (NBTX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $28.56, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Nanobiotix S.A. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 39.9×**. Each dollar of revenue is priced at 39.9×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -2.6%** (5-yr avg -12.5%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -33.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -73.5%**. The company reported a net loss over the last twelve months.
- **Return on equity: 28.4%**. 28.4% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on assets: -35.4%**. Each dollar of assets produces -35.4% of profit.

## Growth
- **Revenue growth (1 yr): 553.2%** (3-yr 89.7%/yr, 5-yr 67.0%/yr). Revenue grew 553.2% over the last year, against 67.0% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 65.3%**. Earnings per share rose 65.3%, slower than revenue, so margins compressed.

## Financial health
- **Interest coverage: -0.7×**. Operating profit covers interest only -0.7×: fragile.
- **Current ratio: 1.09** (quick 1.09). Current assets cover the next year's liabilities 1.09 times.
- **Altman Z-score: 4.04**. A Z-score of 4.04 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Nanobiotix S.A. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (3 analysts). 3 analysts cover Nanobiotix S.A.; the consensus is strong_buy, with an average price target of $54.37 (+90% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 34.7%** (YTD 21.6%, 3-mo -27.7%). The shares are up 34.7% over twelve months including dividends.
- **From 52-week high: -50.0%** (53.7% above the low). Trading 50% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 47**. An RSI of 47 is neutral.
- **Beta (1 yr): 2.28** (volatility 88%). Beta of 2.28 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=NBTX · Page: https://foliofundamentals.com/stocks/nbtx

Not investment advice.